Category: Hypertension

New research, published in the Journal of American Society of Nephrology by The George Institute for International Health in Sydney, has found that lowering blood pressure protects stroke victims with Chronic Kidney Disease from further strokes or heart attacks. Given the high risk of cardiovascular complications in people with Chronic Kidney Disease (CKD), these results have significant implications for millions of people across the world.

A discovery made 25 years ago about how the brain controls blood pressure regulation is only now being explored with the help of scientists from the Howard Florey Institute.Eminent German scientist, Prof Wilfrid Jänig, is in Melbourne this month to collaborate with Florey scientists, Dr Robin McAllen and Dr Bradford Bratton, on his research involving a pathway in the brain that controls blood pressure and may worsen cardiovascular disease.

About half of California adults diagnosed with high blood pressure, or hypertension, do not take medication to lower it, researchers reported at the American Heart Association’s 61st Annual Fall Conference of the Council for High Blood Pressure Research.Of those who do, regularly seeing a doctor makes a big difference in their medication adherence.

As many as 50 percent of overweight men and women with high blood pressure may have hypertension as a result of being overweight, researchers reported at the American Heart Association’s 61st Annual Fall Conference of the Council for High Blood Pressure Research.

Blood flow to the parts of the brain that support memory function differs between people with high blood pressure and those with normal blood pressure, and this difference seems to increase when high blood pressure is treated with medications, researchers reported at the American Heart Association’s 61st Annual Fall Conference of the Council for High Blood Pressure Research.

Physician and hypertension researcher, Professor Friedrich C. Luft, from Berlin, Germany has received the Novartis Award for Hypertension Research from the American Heart Association in Tuscon, Arizona, USA. He was honored for his research on the genetic causes of hypertension, the effects of perturbed electrolyte homeostasis, and the mechanisms of resulting target-organ damage.

Daiichi Sankyo, Inc. announced that the United States Food and Drug Administration (FDA) has approved AZOR(TM) (amlodipine and olmesartan medoxomil) for the treatment of hypertension, also known as high blood pressure.

Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced confirmation of the ability of PS433540 (DARA) to block the angiotensin II (AII) response in a Phase 1 trial in healthy volunteers. Numerous similar studies with other agents that block the renin angiotensin system support that this result is a strong indication that PS433540 can be expected to lower blood pressure in hypertensive patients.

Researchers at the University of Texas Medical Branch at Galveston are trying to determine whether a drug already available to heart patients can also be used to delay delivery in expectant mothers with severe preeclampsia. If so, this groundbreaking study would give hope to hundreds of thousands of women who experience this life-threatening disorder each year.

Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced the initiation of a Phase 2a clinical study of PS433540, the company’s lead internal product candidate. PS433540 is a dual-acting angiotensin and endothelin receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy.